PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Part of paid clinical trials in Worcester, Massachusetts.

Sponsor
University of Massachusetts, Worcester
Study ID
NCT06855329
Status
Recruiting

Conditions

  • Interstitial Lung Disease
  • Progressive Pulmonary Fibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Study Details

This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosis (PPF) classification and establish PPF incidence for key ILD subtypes. Additional exploratory objectives are to 1) Prospectively validate a novel PPF classifier and assess performance durability over time, and 2) Determine whether multi-dimensional PPF prediction outperforms component approaches.

Key Dates

Start date
May 1, 2025
Status verified
Sep 2025
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
500 participants (estimated)

Primary Outcome Measure

Transplant-free survival (TFS) [ Time Frame: 12-months to 24-months (following an observation period from 0 months to 12 months) ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
University of Massachusetts Chan Medical SchoolWorcesterMassachusetts01655
Roberto Caricchio, MD
Betsy Peters, BSN
774-455-4432
University of MichiganAnn ArborMichigan48109
Janelle Pugashetti, MD
University of Texas SouthwesternDallasTexas75390
Chad Newton, MD
214-645-6493
Nighat Sultana, MBBS
214-645-6605
University of VirginiaCharlottesvilleVirginia22908
Tessy Paul, MD
434-243-2398
Yousef Althulth
University of WashingtonSeattleWashington98195
Ganesh Raghu, MD
(206) 598-4967
Katherine Palaeologus
(206)843-0228

Find similar trials in Worcester, MA

Related Studies